FDA Clears Trovafloxacin With Ultra-Broad Indications
Pfizer's once-daily quinolone antibiotic Trovan (trovafloxacin) has beenapproved for marketing in the USA with the broadest number of indications ever awarded at initial registration. This is the first approval of the product, which is scheduled to reach the market in February.
Pfizer will emphasize this ultra-broad utility in its marketing efforts for the antibiotic. Trovafloxacin is available in both oral and intravenous (altrofloxacin) forms and is approved for 14 indications. It is the first antibiotic ever to be licensed for oral prophylactic use during surgery, and promotional activities will concentrate on surgical and respiratory indications for the antibiotic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze